FLTS
72 Hours
Fragment Analysis
Accredited NRL Laboratory
Contact Technical Support
FLT3 mutations occur in approximately 30% of AML cases and serve as major prognostic and therapeutic biomarkers. Identification of these variants is essential for guiding treatment decisions, including the initiation of FLT3-targeted inhibitors such as midostaurin, gilteritinib, and quizartinib. The availability of this clinically validated FDA-approved assay ensures robust, standardized testing aligned with international best practices.
Peripheral Blood (PB) in EDTA or Bone Marrow (BM) Aspirate in EDTA
3-5 mL Peripheral Blood or 1-3 mL Bone Marrow (BM) Aspirate
EDTA
No special preparation is required for this test. You may eat, drink, and take your medications as normal, unless instructed otherwise by your healthcare provider.
This test does not require any special collection or pre-analytical handling. Follow routine specimen collection protocols.
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |